Transcriptogen Ltd.

Transcriptogen Ltd.

Transcriptogen Ltd.

Overview
Headquarters

Paragon House,Lyncombe Vale Road,Bath, London & South East BA2 4LS

Type of Company

Private

Industries

Biotechnology
Holding Companies

Company Description

Transcriptogen Ltd. operates as a drug discovery company to exploit the use of small molecules to inhibit the interaction of transcription factors (TFs) with their cognate DNA-recognition site, thus down-regulating or inhibiting the transcription of disease-related genes. The firm develops and discovers anti-cancer drugs. The company was founded by Khondaker Miraz Rahman, Paul Jackson, and Sheraz Gul and is headquartered in Bath, the United Kingdom.

Executives & Employees

Chief Executive Officer & Director

Chief Scientific Officer & Director

Board of Directors

Head-Life Sciences at Acorn Partners Ltd.

Chief Scientific Officer at Femtogenix Ltd.

Chief Executive Officer & Director at Transcriptogen Ltd.

Paths to Transcriptogen Ltd.
Potential Connections via
Relationship Science
You
Transcriptogen Ltd.
Investors
Details Hidden

Deepbridge work closely with financial advisers and investors to design innovative products, ranging from investment in technology growth companies to asset-backed renewable energy projects. Firm invests in sectors in which they have experience and team is able to take a hands-on approach with investee companies. The industries they focus are disruptive technology, life sciences, renewable energy, sustainable technologies. They can accommodate investments of between £500,000 and £5 million across a variety of sectors. They also partner with innovative and committed management teams to help UK based companies realise their potential and become successful leading-edge businesses.

Details Hidden

King's College London was founded by King George IV and the Duke of Wellington (then Prime Minister) in 1829 as a university college in the tradition of the Church of England. It now welcomes staff and students of all faiths and beliefs.

Details Hidden

AstraZeneca Plc is a holding company, which engages in the research, development and manufacturing of pharmaceutical products. The company produces and commercializes medicines for gastrointestinal, cardiovascular, neuroscience, respiratory and inflammation, oncology, and infectious diseases. Its pipeline consists of azd 4831, azd 8601, medi 0382, tagrisso bloom, durvalumab, selumetinib, lyparza polo, epanova, farxiga and brilinta. The company distributes its products under the following brands: Atacand, Crestor, Onglyza, Nexium, Entocort, Losec, Merrem/Meronem, Carbocaine, Citanest, Diprivan, Marcaine/Sensorcaine. AstraZeneca was founded on April 6, 1999 and is headquartered in London, the United Kingdom.